TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26005259
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac + placebo
Study: 23503879
Drug: PCNL as
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCNL as first treatment (group 2)
Study: 19451765
Drug: 1.8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/d omega-3
Study: 15138617
Drug: 600 ml
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 ml coffee/day and a supplement of 200 microg folic acid/d
Study: 9650545
Drug: Intravenous terazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terazosin (7.5 mg)
Study: 9650545
Drug: Oral terazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terazosin (1 mg on day 1, 2 mg on day 2, and 5 mg on days 3 and 4)
Study: 9650545
Drug: Intravenous terazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terazosin (2.5 mg, 5 mg, or 7.5 mg)
Study: 9650545
Drug: Intravenous terazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terazosin
Study: 9650545
Drug: Oral terazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terazosin
Study: 8031158
Drug: UFT group
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT group (300 mg/day for one year)
Study: 8031158
Drug: non-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-treatment group
Study: 2688079
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam once-daily
Study: 2688079
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen b.i.d.
Study: 31968595
Drug: Preoperative whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative whey protein-infused carbohydrate loading and postoperative early oral feeding (CHO-P)
Study: 27765310
Drug: Intravascular ultrasound
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular ultrasound using the CardioProlific Genesis System followed by local administration of a liquid mixture of iopromide 370 and paclitaxel 1.0 μg/mm3
Study: 27765310
Drug: Drug-eluting balloons
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloons
Study: 22486580
Drug: Antidepressant monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant monotherapy (ADM)
Study: 22486580
Drug: Combination antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antidepressant therapy (CAD)
Study: 10321528
Drug: Intraoperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative mitomycin 0.2 mg/ml for 5 minutes
Study: 10321528
Drug: Postoperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative mitomycin 0.2 mg/ml four times a day for 7 days
Study: 1886479
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution at 26 g.h(‐1)
Study: 1886479
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution at 52 g.h(‐1)
Study: 1886479
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution at 78 g.h(‐1)
Study: 6814928
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion at 3.4 micrograms/min
Study: 6814928
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion at 7.5 micrograms/min
Study: 30921502
Drug: Twice-weekly 28.2-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly 28.2-μg teriparatide injections
Study: 30921502
Drug: Once-weekly 56.5-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly 56.5-μg teriparatide injections
Study: 25899989
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.1 g/kg/day)
Study: 17912165
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (especially abciximab)
Study: 17912165
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (clopidogrel with aspirin)
Study: 17912165
Drug: Intra-coronary (IC)
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-coronary (IC) injection of drugs
Study: 12144585
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg t.d.s. (n=9)
Study: 12144585
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg t.d.s. and Placebo
Study: 1976937
Drug: Specialist clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist clinic treatment
Study: 1976937
Drug: General practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner (GP) treatment
Study: 29912061
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (10 mg oral)
Study: 27651843
Drug: Osteopathic Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manual Treatment (OMT)
Study: 24561029
Drug: Protocolized measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized measurement of MEWS three times daily
Study: 22308559
Drug: Neurodevelopmental Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental Treatment (NDT/Bobath)
Study: 21048211
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of oral aloe vera powder
Study: 17194824
Drug: Intravenous flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flucytosine at 100 mg/kg/day
Study: 17194824
Drug: Oral flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flucytosine at 100 mg/kg/day
Study: 17194824
Drug: Intravenous flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous flucytosine
Study: 17194824
Drug: Oral flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flucytosine
Study: 17194824
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (oral and intravenous)
Study: 1102614
Drug: Alice strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice strain vaccine intranasally
Study: 1102614
Drug: Bivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent inactivated influenza vaccine intramuscularly
Study: 31044450
Drug: HVI injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVI injection with corticosteroid
Study: 31044450
Drug: HVI injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVI injection without corticosteroid
Study: 22168568
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Aspirin for 3 years
Study: 10580457
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg twice per day
Study: 10580457
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice per day
Study: 10580457
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg twice per day
Study: 10580457
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice per day
Study: 27050431
Drug: Memantine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (5 to 20 mg/day; n = 20)
Study: 25234932
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care group (faxed medication care plan and follow-up call)
Study: 25234932
Drug: Minimal care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal care group (admission history, medication reconciliation, patient education, discharge medication list, and medication recommendations)
Study: 21659629
Drug: SCIO‐469 (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIO‐469 (150, 210, or 300 mg preoperative; 210 mg + 90 mg postoperative)
Study: 19528368
Drug: GLP-1 administration
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 administration
Study: 17330056
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training programme (12-week treadmill exercise programme, lactate 2.0 mmol/l)
Study: 9516220
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of troglitazone
Study: 9516220
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of troglitazone
Study: 7977117
Drug: Probucol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 0.5 g, twice daily
Study: 25655470
Drug: ACT-453859 100
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-453859 100 mg once a day
Study: 25655470
Drug: ACT-453859 800
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-453859 800 mg once a day
Study: 25655470
Drug: ACT-453859 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-453859 (dose unspecified)
Study: 8409311
Drug: Eradicating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradicating treatment (colloidal bismuth subcitrate plus metronidazole)
Study: 3752982
Drug: Novobiocin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novobiocin (500 mg) administered orally, twice a day for 27 doses
Study: 3752982
Drug: Rifampin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (300 mg) administered orally, twice a day for 27 doses
Study: 3752982
Drug: Novobiocin and
Normalized name: novobiocin
DrugBank: Novobiocin (DB01051)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novobiocin and rifampin administered in combination
Study: 24996128
Drug: nab‐paclitaxel (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab‐paclitaxel (500 mg/100 ml) administered in 6 weekly intravesical instillations
Study: 20801608
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser therapy (EVLT) (980 nm)
Study: 20801608
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser therapy (EVLT) and High ligation and stripping (HL/S)
Study: 10480957
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg of rhMnSOD
Study: 8735679
Drug: Intrarectal quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal quinine gluconate (12.8 mg kg‐1)
Study: 8735679
Drug: Intramuscular Quinimax
Normalized name: quinidine sulfate Extended Release Oral Tablet [Quinidex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Quinimax (8 mg kg‐1)
Study: 8735679
Drug: Intravenous Quinimax
Normalized name: quinidine sulfate Extended Release Oral Tablet [Quinidex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Quinimax (8 mg kg‐1, 4 h infusion)
Study: 1685090
Drug: bopindolol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 0.5 mg
Study: 1685090
Drug: bopindolol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 1.0 mg
Study: 1685090
Drug: bopindolol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 2.0 mg
Study: 7128662
Drug: Cyclothiazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclothiazide (2.5 mg daily)
Study: 7128662
Drug: Hydrochlorthiazide-amiloride combination
Normalized name: amiloride / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorthiazide-amiloride combination (50 + 5 mg daily)
Study: 29754654
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT), n = 527
Study: 29754654
Drug: Aspirin alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin alone, n = 1525
Study: 27275859
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose omeprazole infusion for 72 hours
Study: 27275859
Drug: Scheduled second-look
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled second-look endoscopy with intravenous omeprazole bolus every 12 hours for 72 hours
Study: 22336262
Drug: Formoterol (extra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (extra daily dose inhaled 8 hours after previous dose)
Study: 20059698
Drug: Acotiamide 100
Normalized name: acetiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide 100 mg t.i.d.
Study: 18537181
Drug: Alpha‐tocopherol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐tocopherol 600 IU/day plus ascorbic acid 500 mg/day
Study: 14633947
Drug: Jejunal gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal gas infusion (12 ml/min for one hour)
Study: 14633947
Drug: Rectal gas
Normalized name: Nitrous Oxide 990 mL in 1 L RECTAL GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal gas infusion (12 ml/min for one hour)
Study: 14633947
Drug: Jejunal gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal gas infusion
Study: 14633947
Drug: Both jejunal
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both jejunal and rectal gas infusion
Study: 8797120
Drug: Combination assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination assessment of SQ and QM
Study: 1639992
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (individualized doses)
Study: 6702238
Drug: 10% fat
Normalized name: Intralipid 10% Fat Emulsion for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% fat solution containing 50 g/l medium chain triglycerides (MCT) and 50 g/l long chain triglycerides (LCT)
Study: 30415310
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg/day for 3 months)
Study: 27317188
Drug: Hydrocodone (HYD)
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocodone (HYD) 20, 40, 60, 80, or 120 mg once daily
Study: 24837512
Drug: MMR SII
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR SII (injection)
Study: 24837512
Drug: MMR II
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR II (injection)
Study: 19456235
Drug: Yeast identified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast identified on wet preparation of vaginal secretions
Study: 15735119
Drug: Ixabepilone (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone (35 mg/m²) alone
Study: 15735119
Drug: Ixabepilone +
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone + Estramustine Phosphate (EMP) (280 mg orally three times daily on days 1 to 5)
Study: 26824902
Drug: Lopimune (Lopinavir/Ritonavir),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopimune (Lopinavir/Ritonavir), 1 capsule twice daily for 2 weeks, self-applied as a vaginal pessary
Study: 20641031
Drug: Calcium 1
Normalized name: Calcium 10-undecenoate
DrugBank: Calcium undecylenate (DB15678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1 g/day
Study: 20641031
Drug: Calcium 600
Normalized name: Calcium 600
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium 600 or 1200 mg/day
Study: 19100933
Drug: Rocuronium (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.06 mg/kg)
Study: 12787711
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose escalation
Study: 12787711
Drug: Hypofractionation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionation and dose individualisation
Study: 11186159
Drug: Phonemic fluency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonemic fluency tests administered individually
Study: 3514333
Drug: sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (250 mg once a day)
Study: 29066327
Drug: Prophylactic vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic vaccine candidate (n = 7)
Study: 20015816
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine + 2 microg/mL fentanyl (Group B)
Study: 20015816
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine + 4 microg/mL fentanyl (Group C)
Study: 11762412
Drug: Rituxan (rituximab)
Normalized name: rituximab Injection [Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituxan (rituximab) in combination with CHOP chemotherapy
Study: 9394690
Drug: 1.03 mg
Normalized name: calcium citrate 1.03 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.03 mg vitamin B-6/d
Study: 9394690
Drug: 1.33 mg
Normalized name: pholcodine 1.33 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.33 mg vitamin B-6/d
Study: 9394690
Drug: 1.73 mg
Normalized name: micafungin 100 MG (equivalent to micafungin sodium 101.73 MG) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.73 mg vitamin B-6/d
Study: 9394690
Drug: 2.39 mg
Normalized name: camphor 43.76 MG / menthol 37.02 MG / methyl salicylate 72.39 MG Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.39 mg vitamin B-6/d
Study: 9394690
Drug: 0.84 mg
Normalized name: ferric sulfate 0.84 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.84 mg vitamin B-6/d
Study: 9394690
Drug: 1.14 mg
Normalized name: caffeine 1.14 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.14 mg vitamin B-6/d
Study: 9394690
Drug: 2.34 mg
Normalized name: BENZALKONIUM CHLORIDE 2.34 mg in 1.8 mL TOPICAL SOAP [TopCare Antibacterial Hand Light Moisturizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.34 mg vitamin B-6/d
Study: 3828178
Drug: 4% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lignocaine 160 mg using a Forrester Spray
Study: 3828178
Drug: 4% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lignocaine 160 mg by 'Laryng‐o‐jet'
Study: 3828178
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered by Forrester Spray
Study: 26679760
Drug: Risperidone plus
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone plus T3 (25 μg daily)
Study: 23564056
Drug: Protamine based
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine based on heparin concentration measured after CPB (Group 2)
Study: 23564056
Drug: Protamine dose
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine dose based on initial heparin dose (Group 1)
Study: 22415336
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of additional whole-grain bread (50 g/1000 kcal)
Study: 22415336
Drug: Intake of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake of dietary fiber (g/1000 kcal)
Study: 19137768
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of doxycycline taken twice daily
Study: 19137768
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of doxycycline taken twice daily
Study: 11352127
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone replacement therapy (HRT)
Study: 9704869
Drug: Lithium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (1200 mg)
Study: 6989592
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy (dietary intensive care, Biguanides, Clofibrate)
Study: 29885068
Drug: Nangibotide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nangibotide (1 mg, 10 mg, and doses ranging from 0.03 to 6 mg kg-1 h-1)
Study: 29885068
Drug: Nangibotide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nangibotide (various doses)
Study: 25052595
Drug: Intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous voriconazole (100 mg two times per day until neutrophils greater than 0.5×10⁹/L)
Study: 25052595
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (200 mg per day)
Study: 22613649
Drug: Oxymatrine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine (600 mg intravenous infusion once a day for a month, then 200 mg oral capsule three times a day)
Study: 22613649
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (silibin meglumine tablet only, same method and dosage as treatment group)
Study: 20955605
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (supervised aerobic interval training sessions, one hour, up to three times weekly)
Study: 18946302
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine and 2 microg/ml fentanyl (group BF)
Study: 10739391
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 5, 10, and 40 ppm
Study: 1533479
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of hepatitis B vaccine, BCG, and inactivated polio vaccine
Study: 27686642
Drug: Oxycodone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.1 mg/kg)
Study: 8003644
Drug: 1 million
Normalized name: Nystatin 1 MILLION U Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 million units of lymphoblastoid IFN-alpha daily for 2 weeks
Study: 8003644
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of lymphoblastoid IFN-alpha daily for 2 weeks